Olema Pharmaceuticals (NASDAQ:OLMA) Director Ian Clark Sells 264,800 Shares of Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Ian Clark sold 264,800 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $29.73, for a total transaction of $7,872,504.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Olema Pharmaceuticals Stock Performance

Shares of Olema Pharmaceuticals stock opened at $27.67 on Wednesday. The stock’s fifty day simple moving average is $18.58 and its 200 day simple moving average is $10.56. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $1.90 billion, a PE ratio of -14.80 and a beta of 1.87. Olema Pharmaceuticals, Inc. has a 12 month low of $2.86 and a 12 month high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.05). On average, research analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

Hedge Funds Weigh In On Olema Pharmaceuticals

A number of large investors have recently modified their holdings of OLMA. Susquehanna International Group LLP increased its position in shares of Olema Pharmaceuticals by 20.6% in the third quarter. Susquehanna International Group LLP now owns 112,277 shares of the company’s stock valued at $1,099,000 after acquiring an additional 19,182 shares during the last quarter. Quarry LP bought a new position in Olema Pharmaceuticals in the third quarter valued at approximately $184,000. Paradigm Biocapital Advisors LP increased its position in shares of Olema Pharmaceuticals by 0.4% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 6,794,172 shares of the company’s stock worth $66,515,000 after purchasing an additional 30,000 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Olema Pharmaceuticals during the 3rd quarter worth approximately $268,000. Finally, Kingdon Capital Management L.L.C. acquired a new stake in shares of Olema Pharmaceuticals in the 3rd quarter valued at approximately $8,361,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Negative Sentiment: Naseem Zojwalla sold 99,509 shares on Dec. 23 at an average $27.66 for ~$2.75M; holding afterward fell to 4,488 shares (a ~95.7% reduction). SEC Form 4 – Zojwalla sale 12/23/2025
• Negative Sentiment: Naseem Zojwalla sold 70,000 shares on Dec. 19 at an average $28.20 for ~$1.97M; his reported direct holding dropped ~40% after that trade. SEC Form 4 – Zojwalla sale 12/19/2025
• Negative Sentiment: Naseem Zojwalla sold 100,000 shares on Dec. 22 at an average $28.04 for ~$2.80M; his combined transactions over the week materially reduced his stake. SEC Form 4 – Zojwalla sale 12/22/2025
• Negative Sentiment: David C. Myles sold 51,000 shares on Dec. 19 at an average $30.46 for ~$1.55M, trimming his position by ~8.5%. SEC Form 4 – Myles sale 12/19/2025
• Negative Sentiment: Director Ian T. Clark sold 264,800 shares on Dec. 19 at an average $29.73 for ~$7.87M — a very large director-level disposal that can amplify market concern. SEC Form 4 – Clark sale 12/19/2025

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. HC Wainwright upped their price target on shares of Olema Pharmaceuticals from $36.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Citigroup increased their target price on Olema Pharmaceuticals from $21.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Guggenheim started coverage on Olema Pharmaceuticals in a research note on Wednesday, October 8th. They issued a “buy” rating and a $20.00 price target on the stock. Zacks Research raised Olema Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Olema Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $40.50.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.